Key facts
- This page summarizes Shelly Wong's Form 4 filing for ALX ONCOLOGY HOLDINGS INC (ALXO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Oct 2025, 16:01.
Shelly Wong - 14 Oct 2025 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)
- Reporting relationship
- SVP, FINANCE AND CAO
- Issuer ticker
- ALXO
- Reported as of
- 14 Oct 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Oct 2025, 16:01:07 UTC
- Prior SEC filing
- 19 Aug 2025
- Next SEC filing
- 07 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shelly Pinto
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Shelly Wong filed Form 4 for ALX ONCOLOGY HOLDINGS INC (ALXO) on 16 Oct 2025.
Change
- Previous filing in this sequence was filed on 19 Aug 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001857740
Primary reporting owner
Pinto Shelly
- Relationship
- SVP, FINANCE AND CAO
- Address
- C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
- Signature
- /s/ Shelly Pinto
- Signature date
- 16 Oct 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALXO
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +140,000
- Change %
- Price
- $0.000000
- Shares after
- 140,000
- Date
- 14 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 140,000
- Exercise price
- $1.70
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.